Sengül Neriman, Aslím Belma, Uçar Gülberk, Yücel Nihal, Işik Sevil, Bozkurt Hatice, Sakaoğullari Zişan, Atalay Fuat
Department of General Surgery, Faculty of Medicine, Abant Izzet Baysal University, Bolu, and Department of Gastrointestinal Surgery, Turkey Yuksek Ihtisas Hospital, Ankara, Turkey.
Dis Colon Rectum. 2006 Feb;49(2):250-8. doi: 10.1007/s10350-005-0267-6.
Inflammatory bowel disease is suggested to result from a dysregulated immune response toward intestinal microflora, which may be restored by probiotic therapy based on the concept of healthy microflora. Ideal probiotic bacteria may be beneficial in inflammatory bowel disease; however, the mechanism of action and the clinical efficacy of probiotic usage are still unclear. In the present study, the effect of exopolysaccharide producing probiotics was evaluated on an experimental colitis model in rats.
Colitis was induced by intracolonic administration of acetic acid. Then, rats were treated daily with two probiotic strains, Lactobacillus delbrueckii subsp. bulgaricus B3 strain (exopolysaccharide of 211 mg/l: high-EPS group) or Lactobacillus delbrueckii subsp. bulgaricus A13 strain (EPS of 27 mg/l: low-EPS group), which were given into the stomach. The non-colitis-fed control group was only treated with high-exopolysaccharide strain. The model-control and control groups were treated only with tap water. Rats were killed after a seven-day treatment period. Disease activity was quantified by use of histologic scores and colonic myeloperoxidase activity, which is a marker of neutrophil infiltration during inflammation.
The enhanced inflammatory response was accompanied by a higher level of myeloperoxidase activity in the colitis group. Histologic scores of colonic damage and myeloperoxidase activity were lower in both probiotic-treated groups compared with those of the colitis control group (P<0.001), although the mentioned scores improved significantly more in the high-EPS group than in the low-EPS group (P<0.001).
Exopolysaccharide-producing probiotics significantly attenuate experimental colitis, which may be mediated by exopolysaccharide in a dose-dependent manner. Therefore, exopolysaccharide-producing probiotics may be a promising therapeutic role in inflammatory bowel disease.
炎症性肠病被认为是由于对肠道微生物群的免疫反应失调所致，基于健康微生物群的概念，益生菌疗法可能会恢复这种失调。理想的益生菌可能对炎症性肠病有益；然而，益生菌的作用机制和临床疗效仍不明确。在本研究中，评估了产胞外多糖益生菌对大鼠实验性结肠炎模型的影响。
通过结肠内注射醋酸诱导结肠炎。然后，每天给大鼠经胃给予两种益生菌菌株，德氏乳杆菌保加利亚亚种B3菌株（胞外多糖含量为211mg/l：高胞外多糖组）或德氏乳杆菌保加利亚亚种A13菌株（胞外多糖含量为27mg/l：低胞外多糖组）。未患结肠炎的对照组仅用高胞外多糖菌株处理。模型对照组和对照组仅用自来水处理。治疗7天后处死大鼠。通过组织学评分和结肠髓过氧化物酶活性来量化疾病活动，结肠髓过氧化物酶活性是炎症期间中性粒细胞浸润的标志物。
结肠炎组炎症反应增强，同时伴有较高水平的髓过氧化物酶活性。与结肠炎对照组相比，两个益生菌治疗组的结肠损伤组织学评分和髓过氧化物酶活性均较低（P<0.001），尽管高胞外多糖组的上述评分改善程度明显高于低胞外多糖组（P<0.001）。
产胞外多糖益生菌可显著减轻实验性结肠炎，这可能由胞外多糖以剂量依赖方式介导。因此，产胞外多糖益生菌在炎症性肠病中可能具有有前景的治疗作用。
